Third Harmonic News Today

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the

U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN...

Celldex drug barzolvolimab has mid-stage results in a chronic inflammatory skin disease that top those of an approved Genentech drug and two experimental Novartis therapies. The biotech is preparing to advance its drug to Phase 3 testing in 2024.

Shares of Third Harmonic Bio, Inc. (THRD) climbs 17% on Tuesday after the company announced its next-generation product candidate, THB335, for the treatment of mast cell-mediated inflammatory diseases.

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory DiseasesSAN FRANCISCO, May 11, 2023 -- Third Harmonic Bio, Inc. , a biopharmaceutical company... | May 11, 2023

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory DiseasesSAN FRANCISCO, March 29, 2023 -- Third Harmonic Bio, Inc. , a biopharmaceutical company... | March 29, 2023

BioPharma

Acelyrin Inc. has raised $300 million in a Series C round to accelerate its treatments for inflammatory diseases.

BioPharma

Investegate announcements from RTW Venture Fund Ltd, Portfolio Company Update: Third Harmonic Bio IPO